Evidence map›Paper›PMID 35454869›Full record

ArticleCancers2022

Communicator-Driven Data Preprocessing Improves Deep Transfer Learning of Histopathological Prediction of Pancreatic Ductal Adenocarcinoma.

Raphael M Kronberg, Lena Haeberle, Melanie Pfaus, Haifeng C Xu, Karina S Krings, Martin Schlensog, Tilman Rau, Aleksandra A Pandyra, Karl S Lang, Irene Esposito and 1 more

Open access · goldAbstract read
In one paragraph

Article in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
3.2field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 23 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Raphael M KronbergDepartment of Molecular Medicine II, Medical Faculty, Heinrich-Heine-University, Universitätsstrasse 1, 40225 Düsseldorf, Germany.ORCID 0000-0002-5444-0189
Lena HaeberleInstitute of Pathology, Medical Faculty, Heinrich-Heine University and University Hospital of Duesseldorf, Moorenstr. 5, 40225 Düsseldorf, Germany.ORCID 0000-0002-8793-568X
Melanie PfausDepartment of Molecular Medicine II, Medical Faculty, Heinrich-Heine-University, Universitätsstrasse 1, 40225 Düsseldorf, Germany.
Haifeng C XuDepartment of Molecular Medicine II, Medical Faculty, Heinrich-Heine-University, Universitätsstrasse 1, 40225 Düsseldorf, Germany.
Karina S KringsDepartment of Molecular Medicine II, Medical Faculty, Heinrich-Heine-University, Universitätsstrasse 1, 40225 Düsseldorf, Germany.
Martin SchlensogInstitute of Pathology, Medical Faculty, Heinrich-Heine University and University Hospital of Duesseldorf, Moorenstr. 5, 40225 Düsseldorf, Germany.
Tilman RauInstitute of Pathology, Medical Faculty, Heinrich-Heine University and University Hospital of Duesseldorf, Moorenstr. 5, 40225 Düsseldorf, Germany.
Aleksandra A PandyraDepartment of Pediatric Oncology, Hematology and Clinical Immunology, Medical Faculty, Center of Child and Adolescent Health, Heinrich-Heine-University, Moorenstrasse 5, 40225 Düsseldorf, Germany.
Karl S LangInstitute of Immunology, Medical Faculty, University of Duisburg-Essen, Hufelandstr. 55, 45147 Essen, Germany.
Irene EspositoInstitute of Pathology, Medical Faculty, Heinrich-Heine University and University Hospital of Duesseldorf, Moorenstr. 5, 40225 Düsseldorf, Germany.ORCID 0000-0002-0554-2402
Philipp A LangDepartment of Molecular Medicine II, Medical Faculty, Heinrich-Heine-University, Universitätsstrasse 1, 40225 Düsseldorf, Germany.
Heinrich Heine University Düsseldorf · DEDüsseldorf University Hospital · DEUniversity of Duisburg-Essen · DE

Funding

Deutsche Forschungsgemeinschaft DFG, SFB974, GRK1949The Anton-Betz Foundation 22/2020The Jürgen Manchot Graduate School (MOI IV)
6 · The paper itself

Abstract

Pancreatic cancer is a fatal malignancy with poor prognosis and limited treatment options. Early detection in primary and secondary locations is critical, but fraught with challenges. While digital pathology can assist with the classification of histopathological images, the training of such networks always relies on a ground truth, which is frequently compromised as tissue sections contain several types of tissue entities. Here we show that pancreatic cancer can be detected on hematoxylin and eosin (H&E) sections by convolutional neural networks using deep transfer learning. To improve the ground truth, we describe a preprocessing data clean-up process using two communicators that were generated through existing and new datasets. Specifically, the communicators moved image tiles containing adipose tissue and background to a new data class. Hence, the original dataset exhibited improved labeling and, consequently, a higher ground truth accuracy. Deep transfer learning of a ResNet18 network resulted in a five-class accuracy of about 94% on test data images. The network was validated with independent tissue sections composed of healthy pancreatic tissue, pancreatic ductal adenocarcinoma, and pancreatic cancer lymph node metastases. The screening of different models and hyperparameter fine tuning were performed to optimize the performance with the independent tissue sections. Taken together, we introduce a step of data preprocessing via communicators as a means of improving the ground truth during deep transfer learning and hyperparameter tuning to identify pancreatic ductal adenocarcinoma primary tumors and metastases in histological tissue sections.

Indexed as

computer visiondeep learningmetastasespancreatic cancerpancreatic ductal adenocarcinomatransfer learning

Identifiers

PMID35454869
PMCPMC9031738
OpenAlexW4224034222

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.